JP5504484B2 - ウレア誘導体および関連ジアミン、これらの製造方法および使用 - Google Patents

ウレア誘導体および関連ジアミン、これらの製造方法および使用 Download PDF

Info

Publication number
JP5504484B2
JP5504484B2 JP2010516062A JP2010516062A JP5504484B2 JP 5504484 B2 JP5504484 B2 JP 5504484B2 JP 2010516062 A JP2010516062 A JP 2010516062A JP 2010516062 A JP2010516062 A JP 2010516062A JP 5504484 B2 JP5504484 B2 JP 5504484B2
Authority
JP
Japan
Prior art keywords
phenyl
diphenylpropyl
thiazol
chloro
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010516062A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010533185A5 (enExample
JP2010533185A (ja
Inventor
デプレ,ピエール
フオツシユ,クリストフアー
ハリントン,ポール
ライブリー,サラ・イー
パツタビラーマン,カナカ
セント・ジーン,デイビツド
トマル−レブ,タウ
ウエーン,ポール
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2010533185A publication Critical patent/JP2010533185A/ja
Publication of JP2010533185A5 publication Critical patent/JP2010533185A5/ja
Application granted granted Critical
Publication of JP5504484B2 publication Critical patent/JP5504484B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/44Acylated amino or imino radicals
    • C07D277/46Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2010516062A 2007-07-10 2008-07-10 ウレア誘導体および関連ジアミン、これらの製造方法および使用 Expired - Fee Related JP5504484B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95905807P 2007-07-10 2007-07-10
US60/959,058 2007-07-10
PCT/US2008/008508 WO2009009122A2 (en) 2007-07-10 2008-07-10 Derivatives of urea and related diamines, methods for their manufacture, and uses therefor

Publications (3)

Publication Number Publication Date
JP2010533185A JP2010533185A (ja) 2010-10-21
JP2010533185A5 JP2010533185A5 (enExample) 2011-04-21
JP5504484B2 true JP5504484B2 (ja) 2014-05-28

Family

ID=39884677

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010516062A Expired - Fee Related JP5504484B2 (ja) 2007-07-10 2008-07-10 ウレア誘導体および関連ジアミン、これらの製造方法および使用

Country Status (6)

Country Link
US (1) US8324396B2 (enExample)
EP (1) EP2176247A2 (enExample)
JP (1) JP5504484B2 (enExample)
AU (1) AU2008275595B2 (enExample)
CA (1) CA2692598A1 (enExample)
WO (1) WO2009009122A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2885129B1 (fr) 2005-04-29 2007-06-15 Proskelia Sas Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation.
DE602006010905D1 (de) * 2005-11-25 2010-01-14 Galapagos Sas Harnstoff-derivate als calcium-rezeptor-modulatoren
WO2008139947A1 (ja) * 2007-05-08 2008-11-20 Ajinomoto Co., Inc. 下痢の予防又は治療剤
US9725427B2 (en) 2012-03-16 2017-08-08 Biohaven Pharmaceutical Holding Company Limited Prodrugs of riluzole and their method of use
CN102701992B (zh) * 2012-07-03 2014-01-15 重庆医科大学 一种抗肿瘤化合物及其药学上可接受的盐、及制备方法和应用
CN103992236B (zh) * 2014-04-29 2016-05-18 于非 一种新型靶向性抗肿瘤药物及其制备方法与应用
EP4172149A4 (en) * 2020-06-29 2024-09-04 Bacainn Biotherapeutics, Ltd. PROBENECID COMPOUNDS FOR THE TREATMENT OF INFLAMMASOME-MEDIATED LUNG DISEASE

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58109464A (ja) 1981-12-23 1983-06-29 Nippon Paint Co Ltd アミノ酸化合物、その製法ならびに触媒
IL67417A (en) * 1982-01-26 1989-10-31 American Cyanamid Co Antiatherosclerotic substituted ureas,process for their preparation and pharmaceutical compositions containing them
US4994465A (en) * 1989-02-17 1991-02-19 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic trisubstituted urea compounds
US5153226A (en) 1989-08-31 1992-10-06 Warner-Lambert Company Acat inhibitors for treating hypocholesterolemia
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
JPH0841006A (ja) 1994-08-05 1996-02-13 Nisshin Flour Milling Co Ltd ジウレア誘導体
CZ290670B6 (cs) 1994-10-21 2002-09-11 Nps Pharmaceuticals, Inc. Sloučeniny modulující receptory anorganických iontů a farmaceutický prostředek, který je obsahuje
JPH10195037A (ja) 1996-02-15 1998-07-28 Tanabe Seiyaku Co Ltd フェノール誘導体
JPH11139969A (ja) 1997-08-07 1999-05-25 Tanabe Seiyaku Co Ltd 医薬組成物
US6365617B1 (en) 1999-06-29 2002-04-02 Ortho-Mcneil Pharmaceutical, Inc. Indole and indazole urea-peptoids as thrombin receptor antagonists
FR2820136A1 (fr) 2001-01-26 2002-08-02 Aventis Pharma Sa Nouveaux derives de l'uree, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
FR2885129B1 (fr) * 2005-04-29 2007-06-15 Proskelia Sas Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation.
DE602006010905D1 (de) * 2005-11-25 2010-01-14 Galapagos Sas Harnstoff-derivate als calcium-rezeptor-modulatoren
GB0613674D0 (en) * 2006-07-10 2006-08-16 Proskelia Sas Derivatives of urea and related diamines, methods for their manufacture, and uses therefor

Also Published As

Publication number Publication date
AU2008275595B2 (en) 2013-11-14
US8324396B2 (en) 2012-12-04
WO2009009122A2 (en) 2009-01-15
AU2008275595A1 (en) 2009-01-15
US20090054463A1 (en) 2009-02-26
WO2009009122A3 (en) 2009-06-25
JP2010533185A (ja) 2010-10-21
EP2176247A2 (en) 2010-04-21
CA2692598A1 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
US6346532B1 (en) Amide derivatives or salts thereof
JP5504484B2 (ja) ウレア誘導体および関連ジアミン、これらの製造方法および使用
US8242139B2 (en) Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme
US7265138B2 (en) Vanilloid receptor ligands and their use in treatments
US7141596B2 (en) Inhibitors of proteins that bind phosphorylated molecules
US7767701B2 (en) Chemical compounds
CA3117200A1 (en) Tyk2 inhibitors and uses thereof
JP5478496B2 (ja) カルシウム受容体調節剤
US12110285B2 (en) Substituted pyridine derivatives as SARM1 inhibitors
JP2010534647A (ja) 2−アザ−ビシクロ[3.3.0]オクタン誘導体
EP3357915A1 (en) Heterocycle amines with anti-inflammatory activity
AU2006297089A1 (en) Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors
AU2007271918A1 (en) Derivatives of urea and related diamines, methods for their manufacture, and uses therefor
US20050240021A1 (en) Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators
MX2011006343A (es) Tiazoles como ligandos del receptor de cannabinoide.
US20060194854A1 (en) New 2-substituted - 1,3-thiazole compounds
CZ300937B6 (cs) Nové deriváty aminothiazolu, zpusob jejich prípravy a farmaceutické kompozice, které je obsahují
PT95317A (pt) Processo para a obtencao de um novo composto tiazol destinado
AU2006316705A1 (en) Urea derivatives useful as calcium receptor modulators
US20090203692A1 (en) Novel chemical compounds
EP0575614A1 (en) Thiazole derivatives
JPH0223542B2 (enExample)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110302

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20130307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130521

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130820

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130919

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140124

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140218

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140225

R150 Certificate of patent or registration of utility model

Ref document number: 5504484

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees